>>It's not a new drug, it's been around so long that other companies could make the generic form. So, Janssen would lay out the big buck (extremely large bucks) to apply to FDA to get it approved and then US pharmaceuticals could make the generic and Janssen would likely lose money on the whole deal not even breaking even.<< So this is the crux of the problem--- the FDA process is EXPENSIVE and the company who lays out the money may not get it back in sales. It's about MONEY, not safety. So is there some way to circumvent this? Where can we apply pressure to smooth out the red tape? >>The makers of Motillium, Janssen, tried for 14 years to get the drug past the FDA and the makers of Reglan (which has its own list of serious side effects, especially for use beyond a few weeks) blocked it (on the side) each time they tried. They say that it costs them too much to keep submitting it<< Is this true? Is there a way to document this? The domperidone situation has been operating under the radar for several years. Now that it has surfaced and drawn attention, it is time to tackle it officially. The only question is of where is the best place to start? ~Lisa Marasco *********************************************** To temporarily stop your subscription: set lactnet nomail To start it again: set lactnet mail (or digest) To unsubscribe: unsubscribe lactnet All commands go to [log in to unmask] The LACTNET mailing list is powered by L-Soft's renowned LISTSERV(R) list management software together with L-Soft's LSMTP(R) mailer for lightning fast mail delivery. For more information, go to: http://www.lsoft.com/LISTSERV-powered.html